Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Changhoon Yoo

Showing results (71-80 of 250) with videos related to

Pageof 25
Sort By:
Journal for Immunotherapy of Cancer|May 29, 2020
Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancerChanghoon Yoo, Do-Youn Oh, Hye Jin Choi, et al.
Scientific Reports|February 19, 2024
Somatostatin receptor 2 (SSTR2) expression is associated with better clinical outcome and prognosis in rectal neuroendocrine tumorsJoo Young Kim, Jisup Kim, Yong-Il Kim, et al.
Investigational New Drugs|December 12, 2018
Efficacy and safety of lanreotide in Korean patients with metastatic, well-differentiated gastroenteropancreatic-neuroendocrine tumors: a retrospective analysisJunho Kang, Changhoon Yoo, Hee-Sang Hwang, et al.
Liver Cancer|October 21, 2020
Real-World Efficacy and Safety of Lenvatinib in Korean Patients with Advanced Hepatocellular Carcinoma: A Multicenter Retrospective AnalysisJaekyung Cheon, Hong Jae Chon, Yeonghak Bang, et al.
Journal of Hepato-Biliary-Pancreatic Sciences|July 9, 2020
Prognostic implication of high grade biliary intraepithelial neoplasia in bile duct resection margins in patients with resected perihilar cholangiocarcinomaDakyum Shin, Sojung Lee, Jae Hoon Lee, et al.
Liver Cancer|April 21, 2025
Higher Risk of Proteinuria with Atezolizumab plus Bevacizumab than Lenvatinib in First-Line Systemic Treatment for Hepatocellular CarcinomaJiwon Yang, Won-Mook Choi, Hyung-Don Kim, et al.
European Radiology|August 20, 2020
Multiparametric MRI for prediction of treatment response to neoadjuvant FOLFIRINOX therapy in borderline resectable or locally advanced pancreatic cancerJi Hun Kang, Seung Soo Lee, Jin Hee Kim, et al.
JCO Clinical Cancer Informatics|December 2, 2025
Predicting Chemotherapy Response in Patients With Advanced or Metastatic Pancreatic Cancer Using Machine LearningJamin Koo, Gyucheol Choi, Jaekyung Cheon, et al.
The Korean Journal of Internal Medicine|September 11, 2010
Modified number of extranodal involved sites as a prognosticator in R-CHOP-treated patients with disseminated diffuse large B-cell lymphomaChanghoon Yoo, Shin Kim, Byeong Seok Sohn, et al.
Anticancer Research|August 28, 2025
A Phase II Trial of Pemetrexed Plus Oxaliplatin in Patients With Advanced Biliary Tract Cancer After Failure of Gemcitabine Plus Cisplatin-based ChemotherapyJwa Hoon Kim, Changhoon Yoo, Hyehyun Jeong, et al.
Pageof 25

Showing results (71-80 of 250) with videos related to

Sort By:
Pageof 25
Journal for Immunotherapy of Cancer|May 29, 2020
Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancerChanghoon Yoo, Do-Youn Oh, Hye Jin Choi, et al.
Scientific Reports|February 19, 2024
Somatostatin receptor 2 (SSTR2) expression is associated with better clinical outcome and prognosis in rectal neuroendocrine tumorsJoo Young Kim, Jisup Kim, Yong-Il Kim, et al.
Investigational New Drugs|December 12, 2018
Efficacy and safety of lanreotide in Korean patients with metastatic, well-differentiated gastroenteropancreatic-neuroendocrine tumors: a retrospective analysisJunho Kang, Changhoon Yoo, Hee-Sang Hwang, et al.
Liver Cancer|October 21, 2020
Real-World Efficacy and Safety of Lenvatinib in Korean Patients with Advanced Hepatocellular Carcinoma: A Multicenter Retrospective AnalysisJaekyung Cheon, Hong Jae Chon, Yeonghak Bang, et al.
Journal of Hepato-Biliary-Pancreatic Sciences|July 9, 2020
Prognostic implication of high grade biliary intraepithelial neoplasia in bile duct resection margins in patients with resected perihilar cholangiocarcinomaDakyum Shin, Sojung Lee, Jae Hoon Lee, et al.
Liver Cancer|April 21, 2025
Higher Risk of Proteinuria with Atezolizumab plus Bevacizumab than Lenvatinib in First-Line Systemic Treatment for Hepatocellular CarcinomaJiwon Yang, Won-Mook Choi, Hyung-Don Kim, et al.
European Radiology|August 20, 2020
Multiparametric MRI for prediction of treatment response to neoadjuvant FOLFIRINOX therapy in borderline resectable or locally advanced pancreatic cancerJi Hun Kang, Seung Soo Lee, Jin Hee Kim, et al.
JCO Clinical Cancer Informatics|December 2, 2025
Predicting Chemotherapy Response in Patients With Advanced or Metastatic Pancreatic Cancer Using Machine LearningJamin Koo, Gyucheol Choi, Jaekyung Cheon, et al.
The Korean Journal of Internal Medicine|September 11, 2010
Modified number of extranodal involved sites as a prognosticator in R-CHOP-treated patients with disseminated diffuse large B-cell lymphomaChanghoon Yoo, Shin Kim, Byeong Seok Sohn, et al.
Anticancer Research|August 28, 2025
A Phase II Trial of Pemetrexed Plus Oxaliplatin in Patients With Advanced Biliary Tract Cancer After Failure of Gemcitabine Plus Cisplatin-based ChemotherapyJwa Hoon Kim, Changhoon Yoo, Hyehyun Jeong, et al.
Pageof 25